In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 pill to identify Risk-free dosing program. Added individuals might be enrolled in the determined monotherapy dosign program. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase C, contributors https://ankeu009grb1.wikihearsay.com/user